Pei Zhou

This study shows that targeting REV1 in colorectal cancer enhances chemotherapy sensitivity in a context-dependent manner and inhibits organoid growth.

This paper identifies TBB as a small molecule inhibitor of MESH1 that suppresses ferroptosis in vitro and reduces neuronal death in an Alzheimer's disease model.

This study identifies REV7 as a novel binding partner of ATRIP that inhibits ATR kinase activity and negatively regulates ATR signaling.

This study shows that inhibiting REV1, a TLS polymerase, increases trinucleotide repeat instability in human cells, suggesting REV1 protects against TNR mutagenesis.

This paper evaluates AlphaFold 3's ability to predict D-peptide chirality, fold, and binding pose in heterochiral complexes and finds it performs poorly, with a high chirality violation rate.

The paper shows that AR inhibition in prostate cancer causes DNA replication stress, which can be exploited by combining with a TLS inhibitor to enhance treatment efficacy.

DexDesign is a new OSPREY-based algorithm for designing D-peptide inhibitors targeting PDZ domains, generating peptides predicted to bind tighter than endogenous ligands.